These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 23257624)
21. Changes in Body Mass Index in Girls with Idiopathic Central Precocious Puberty under Gonadotropin-Releasing Hormone Analogue Therapy: The Spanish Registry. Corripio R; Soriano-Guillén L; Herrero FJ; Cañete R; Castro-Feijoó L; Escribano A; Espino R; Labarta JI; Argente J Horm Res Paediatr; 2016; 86(3):154-160. PubMed ID: 27529349 [TBL] [Abstract][Full Text] [Related]
22. [Impact of gonadotropin-releasing hormone analogs treatment on final height in girls with central precocious puberty]. Chen SK; Fan X; Tang Q Zhongguo Dang Dai Er Ke Za Zhi; 2009 May; 11(5):374-6. PubMed ID: 19470261 [TBL] [Abstract][Full Text] [Related]
23. Serum sex hormone-binding globulin levels in healthy children and girls with precocious puberty before and during gonadotropin-releasing hormone agonist treatment. Sørensen K; Andersson AM; Skakkebaek NE; Juul A J Clin Endocrinol Metab; 2007 Aug; 92(8):3189-96. PubMed ID: 17519314 [TBL] [Abstract][Full Text] [Related]
24. Combined use of growth hormone and gonadotropin-releasing hormone analogues: the national cooperative growth study experience. Kohn B; Julius JR; Blethen SL Pediatrics; 1999 Oct; 104(4 Pt 2):1014-8. PubMed ID: 10506254 [TBL] [Abstract][Full Text] [Related]
25. Effect of gonadotropin-releasing hormone analogue on final adult height among Jordanian children with precocious puberty. Swaiss HH; Khawaja NM; Farahid OH; Batieha AM; Ajlouni KM Saudi Med J; 2017 Nov; 38(11):1101-1107. PubMed ID: 29114697 [TBL] [Abstract][Full Text] [Related]
26. Influence of GnRH analog therapy on body mass in central precocious puberty. Głab E; Barg E; Wikiera B; Grabowski M; Noczyńska A Pediatr Endocrinol Diabetes Metab; 2009; 15(1):7-11. PubMed ID: 19454183 [TBL] [Abstract][Full Text] [Related]
27. Growth outcome during GnRH agonist treatments for slowly progressive central precocious puberty. Massart F; Federico G; Harrell JC; Saggese G Neuroendocrinology; 2009; 90(3):307-14. PubMed ID: 19641297 [TBL] [Abstract][Full Text] [Related]
28. [Treatment of central precocious puberty with Gonadotropin-Releasing Hormone agonist (triptorelin) in girls: breast development, skeletal maturation, height and weight evolution during and after treatment]. Messaaoui A; Massa G; Tenoutasse S; Heinrichs C Rev Med Brux; 2005 Feb; 26(1):27-32. PubMed ID: 15816337 [TBL] [Abstract][Full Text] [Related]
29. Determinants of growth during gonadotropin-releasing hormone analog therapy for precocious puberty. Weise M; Flor A; Barnes KM; Cutler GB; Baron J J Clin Endocrinol Metab; 2004 Jan; 89(1):103-7. PubMed ID: 14715835 [TBL] [Abstract][Full Text] [Related]
30. Use of a potent, long acting agonist of gonadotropin-releasing hormone in the treatment of precocious puberty. Boepple PA; Mansfield MJ; Wierman ME; Rudlin CR; Bode HH; Crigler JF; Crawford JD; Crowley WF Endocr Rev; 1986 Feb; 7(1):24-33. PubMed ID: 2937629 [TBL] [Abstract][Full Text] [Related]
31. Reduction of baseline body mass index under gonadotropin-suppressive therapy in girls with idiopathic precocious puberty. Arrigo T; De Luca F; Antoniazzi F; Galluzzi F; Segni M; Rosano M; Messina MF; Lombardo F Eur J Endocrinol; 2004 Apr; 150(4):533-7. PubMed ID: 15080784 [TBL] [Abstract][Full Text] [Related]
32. Effect of gonadotropin-releasing hormone agonist treatment in boys with central precocious puberty: final height results. Mul D; Bertelloni S; Carel JC; Saggese G; Chaussain JL; Oostdijk W Horm Res; 2002; 58(1):1-7. PubMed ID: 12169774 [TBL] [Abstract][Full Text] [Related]
34. Efficacy of combined treatment with growth hormone and gonadotropin releasing hormone analogue in children with poor prognosis of adult height. Toumba M; Bacopoulou I; Savva SC; Skordis N Indian Pediatr; 2007 Jul; 44(7):497-502. PubMed ID: 17684302 [TBL] [Abstract][Full Text] [Related]
35. Girls with idiopathic central precocious puberty did not display substatial changes in body mass index after treatment with gonadotropin-releasing hormone analogues. Uldbjerg CS; Lim YH; Renault CH; Hansen D; Juul A; Bräuner EV; Jensen RB Acta Paediatr; 2024 Jul; 113(7):1602-1611. PubMed ID: 38506052 [TBL] [Abstract][Full Text] [Related]
36. Body mass index evolution and ovarian function in adolescent girls who received GnRH agonist treatment for central precocious puberty or early and fast puberty. Buyukyilmaz G; Koca SB; Adiguzel KT; Gurbuz F; Boyraz M J Pediatr Endocrinol Metab; 2023 Nov; 36(11):1044-1051. PubMed ID: 37735929 [TBL] [Abstract][Full Text] [Related]
37. MANAGEMENT OF ENDOCRINE DISEASE: Long-term outcomes of the treatment of central precocious puberty. Guaraldi F; Beccuti G; Gori D; Ghizzoni L Eur J Endocrinol; 2016 Mar; 174(3):R79-87. PubMed ID: 26466612 [TBL] [Abstract][Full Text] [Related]
38. Idiopathic precocious puberty versus puberty in adopted children; auxological response to gonadotrophin-releasing hormone agonist treatment and final height. Kempers MJ; Otten BJ Eur J Endocrinol; 2002 Nov; 147(5):609-16. PubMed ID: 12444892 [TBL] [Abstract][Full Text] [Related]
39. Bone mass at final height in precocious puberty after gonadotropin-releasing hormone agonist with and without calcium supplementation. Antoniazzi F; Zamboni G; Bertoldo F; Lauriola S; Mengarda F; Pietrobelli A; Tatò L J Clin Endocrinol Metab; 2003 Mar; 88(3):1096-101. PubMed ID: 12629090 [TBL] [Abstract][Full Text] [Related]
40. Body mass index and body composition in adolescents treated with gonadotropin-releasing hormone analogue triptorelin depot for central precocious puberty: data at near final height. Chiocca E; Dati E; Baroncelli GI; Mora S; Parrini D; Erba P; Bertelloni S Neuroendocrinology; 2009; 89(4):441-7. PubMed ID: 19176945 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]